RecruitingRecruiting
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
NCT07804186 · IDEAYA Biosciences
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
About this study
This study will enroll participants who are at high-risk for metastatic disease and who have completed primary local therapy (i.e., plaque brachytherapy, proton beam radiation, or enucleation) for their UM without evidence of active local or metastatic disease after this treatment.
The Treatment Arm will have participants who have completed PLT and will receive darovasertib + crizotinib.
The Observation Arm participants will not receive darovasertib + crizotinib but will be observed and followed for disease recurrence and survival (Control Arm)
Participants in both arms will be followed for up to five years to assess longer term outcomes such as tumor recurrence and survival.
Eligibility criteria
Inclusion Criteria:
* Primary Uveal Melanoma, classified as high-risk of relapse (AJCC Stage II or Stage 3)
* Completed primary local therapy (enucleation, proton beam therapy, plaque brachytherapy)
* ECOG performance status of 0 or 1
* Adequate organ function
* Age 18 or older
* Written informed consent and ability to comply
* Primary local therapy completed within 120 days before C1D1/randomization.
* Contraception requirements
Exclusion Criteria:
* Previous systemic treatment for Uveal Melanoma
* Clinical or radiological evidence of metastatic UM
* Concurrent malignant disease with the following exceptions: malignancies that were treated curatively and have not recurred within 2 years prior to randomization, completely resected basal cell and squamous cell skin cancers, any malignancy considered to be indolent and never required systemic therapy, and any type of carcinoma in situ receiving curative therapy (resection)
* Known AIDS related illness
* History of interstitial lung disease, active pneumonitis, or history of noninfectious pneumonitis requiring steroids
* History of syncope may be exclusionary, but will be reviewed on a case-by-case basis
* Active Hepatitis B or C infection
* Any gastrointestinal condition (eg, inflammatory bowel disease, major gastric or intestinal surgery) that could affect absorption or ability to swallow
* Females who are pregnant or breastfeeding
* Impaired cardiac function
* History of stroke within the last 6 months of randomization
* Ongoing use of medication use for infections, other antineoplastic therapies, or other prohibited medications, including medications that interact with the metabolism of darovasertib+crizotinib
* allergy to mammalian meat products or gelatin
Study design
Enrollment target: 450 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-04
Estimated completion: 2034-04
Last updated: 2026-11-12
Interventions
Drug: DarovasertibDrug: Crizotinib (Xalkori)
Primary outcomes
- • Median relapse-free survival (Approximately 5 years)
Sponsor
IDEAYA Biosciences · industry
Contacts & investigators
ContactIDEAYA Clinical Trials · contact · IDEAYAClinicalTrials@ideayabio.com · +1-855-433-2246
ContactHolger Thurm · contact · hthurm@ideayabio.com
All locations (29)
Honor Health Research InstituteRecruiting
Scottsdale, Arizona, United States
UCLA Medical CenterNot Yet Recruiting
Los Angeles, California, United States
Angeles ClinicNot Yet Recruiting
Los Angeles, California, United States
University of California, San DiegoNot Yet Recruiting
San Diego, California, United States
Sutter Health CPMCNot Yet Recruiting
San Francisco, California, United States
University of California, San FranciscoNot Yet Recruiting
San Francisco, California, United States
University of MiamiNot Yet Recruiting
Miami, Florida, United States
USF Health Eye InstituteNot Yet Recruiting
Tampa, Florida, United States
Dana Farber Cancer InstituteNot Yet Recruiting
Boston, Massachusetts, United States
Cancer Hematology Centers Western MichiganNot Yet Recruiting
Grand Rapids, Michigan, United States
Columbia University - Herbert Irving Comprehensive Cancer CenterNot Yet Recruiting
New York, New York, United States
Memorial Sloan Kettering Cancer CenterNot Yet Recruiting
New York, New York, United States
Northwell HealthNot Yet Recruiting
New York, New York, United States
Duke Cancer CenterRecruiting
Raleigh, North Carolina, United States
Cleveland ClinicRecruiting
Cleveland, Ohio, United States
Wills Eye Hospital at Thomas Jefferson UniversityRecruiting
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute (SCRI)Recruiting
Nashville, Tennessee, United States
The University of Texas Southwestern Medical CenterNot Yet Recruiting
Dallas, Texas, United States
UT MD Anderson Cancer CenterNot Yet Recruiting
Houston, Texas, United States
University of Wisconsin HealthNot Yet Recruiting
Madison, Wisconsin, United States
Princess Alexandra HospitalNot Yet Recruiting
Woolloongabba, Queensland, Australia
Alfred HealthNot Yet Recruiting
Melbourne, Victoria, Australia
Universite de Montreal - Centre de Recherche du Centre Hospitalier de l'Universite de MontrealNot Yet Recruiting
Montréal, Ontario, Canada
Princess Margaret Cancer CentreRecruiting
Toronto, Ontario, Canada
Hadassah Medical CenterNot Yet Recruiting
Jerusalem, Israel
Sheba Medical CenterNot Yet Recruiting
Ramat Gan, Israel
University of Zurich HospitalNot Yet Recruiting
Zurich, Switzerland
Beatson West of Scotland Cancer CentreNot Yet Recruiting
Glasgow, United Kingdom
Mount Vernon HospitalNot Yet Recruiting
Northwood, United Kingdom